/2017

Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017

San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced new preclinical data [...]

2017-10-06T18:31:58-07:00September 7th, 2017|

Forge Therapeutics and Evotec to present preclinical data on novel antibiotic program at 2017 ASM/ESCMID Conference

San Diego, California, August 29, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced today that the [...]

2017-10-04T14:17:29-07:00August 29th, 2017|

Forge Therapeutics forms scientific advisory board with world renowned antibiotic and drug development experts

San Diego, California, July 26, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]

2017-10-09T22:00:57-07:00July 25th, 2017|

Forge and Evotec Present First Efficacy Data for LpxC Inhibitor in UTI Model at ASM Microbe 2017

San Diego, California, June 3, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]

2017-10-11T16:19:13-07:00June 3rd, 2017|
Load More Posts